About all

Satellite lesions yeast infection. Satellite Lesions in Yeast Infections: Symptoms, Appearance, and Treatment Options

by alexxlab

How do satellite lesions appear in yeast infections. What are the main symptoms of candidiasis. Which treatments are most effective for yeast infections with satellite lesions. How can you distinguish between different types of fungal skin infections.

Содержание

Understanding Satellite Lesions in Yeast Infections

Yeast infections, particularly those caused by Candida species, can present with a characteristic feature known as satellite lesions. These are small, isolated lesions that appear separate from the main area of infection. Understanding the nature and significance of these satellite lesions is crucial for proper diagnosis and treatment of yeast infections.

What are satellite lesions?

Satellite lesions are small, distinct areas of infection that develop around the edges of the main infected area. They typically appear as tiny red or white spots, pustules, or papules. These lesions are a hallmark sign of Candida infections and can help differentiate yeast infections from other types of skin conditions.

Why do satellite lesions occur?

Satellite lesions form when yeast cells spread from the primary site of infection to nearby skin areas. This spread occurs through a process called “budding,” where new yeast cells form and detach from the parent cell. The ability of Candida to produce these satellite lesions is one of the reasons yeast infections can be persistent and challenging to treat.

Identifying Symptoms of Yeast Infections with Satellite Lesions

Recognizing the symptoms of a yeast infection, especially when satellite lesions are present, is essential for prompt and effective treatment. The hallmarks of Candida infection include:

  • Bright erythema (redness) of the affected area
  • Fragile papulopustules (small, raised bumps that may contain pus)
  • Satellite lesions around the main infected area
  • Itching, burning, or soreness of the affected skin
  • A rash that may be scaly, raw, or moist

In cases of genital yeast infections, additional symptoms may include:

  • Vaginal or penile discharge (often thick and white, resembling cottage cheese)
  • Discomfort during urination or sexual intercourse
  • Swelling and irritation of the genitals

Diagnostic Approaches for Yeast Infections

Accurate diagnosis of yeast infections, particularly those with satellite lesions, is crucial for appropriate treatment. Healthcare providers typically use a combination of clinical examination and laboratory tests to confirm the presence of a Candida infection.

Clinical examination

During a physical examination, healthcare providers look for characteristic signs of yeast infections, including:

  • The presence of satellite lesions
  • Erythema and inflammation of the affected area
  • Scaling or fissuring of the skin
  • White, cottage cheese-like discharge (in genital infections)

Laboratory tests

To confirm the diagnosis, several laboratory tests may be performed:

  • Microscopic examination: A sample from the affected area is examined under a microscope to identify Candida organisms.
  • Fungal culture: This test can identify the specific species of Candida causing the infection.
  • Skin biopsy: In rare cases, a small skin sample may be taken to rule out other conditions.

Treatment Options for Yeast Infections with Satellite Lesions

Effective treatment of yeast infections with satellite lesions typically involves a combination of topical and/or oral antifungal medications. The choice of treatment depends on the severity and location of the infection.

Topical antifungal treatments

For mild to moderate infections, topical antifungal medications are often the first line of treatment. These may include:

  • Imidazole creams (e.g., clotrimazole, miconazole)
  • Nystatin cream or ointment
  • Ciclopirox cream

These medications are typically applied directly to the affected area and surrounding skin, including satellite lesions, for 1-2 weeks or as directed by a healthcare provider.

Oral antifungal medications

For more severe or recurrent infections, oral antifungal medications may be prescribed. Common options include:

  • Fluconazole
  • Itraconazole
  • Ketoconazole

These medications are taken by mouth and work systemically to eliminate the Candida infection throughout the body.

Preventing Recurrence of Yeast Infections

Preventing the recurrence of yeast infections, especially those with satellite lesions, involves addressing predisposing factors and maintaining good hygiene practices.

Addressing predisposing factors

Several factors can increase the risk of developing yeast infections:

  • Occlusion: Keeping the affected area dry and well-ventilated can help prevent recurrence.
  • Maceration: Avoiding prolonged exposure to moisture can reduce the risk of infection.
  • Altered barrier function: Treating underlying skin conditions that may compromise skin integrity is important.

Hygiene practices

Maintaining good hygiene can help prevent yeast infections:

  • Keep the affected area clean and dry
  • Wear breathable, cotton underwear
  • Avoid tight-fitting clothing
  • Change out of wet or sweaty clothes promptly
  • Avoid using scented products in the genital area

Differentiating Yeast Infections from Other Skin Conditions

Yeast infections with satellite lesions can sometimes be confused with other skin conditions. Understanding the key differences can help in accurate diagnosis and appropriate treatment.

Bacterial infections

Unlike yeast infections, bacterial skin infections often present with:

  • More intense redness and warmth
  • Lack of satellite lesions
  • Possible presence of pus or honey-colored crusts

Dermatitis

Dermatitis, such as eczema or contact dermatitis, may share some similarities with yeast infections but typically:

  • Does not have satellite lesions
  • May have a more diffuse distribution
  • Often has a known trigger (e.g., allergen or irritant)

Psoriasis

Psoriasis can sometimes be mistaken for a yeast infection, but it usually:

  • Has more defined, silvery scales
  • Lacks the characteristic satellite lesions of yeast infections
  • Often affects areas like elbows, knees, and scalp

Special Considerations for Genital Yeast Infections

Genital yeast infections require special attention due to their sensitive location and potential for sexual transmission.

Differences in appearance

Genital yeast infections may present differently from cutaneous infections:

  • Vaginal infections often have a thick, white discharge
  • Male genital infections may present as balanitis (inflammation of the glans penis)
  • Satellite lesions may be less prominent in moist areas

Sexual transmission

While not classified as a sexually transmitted infection, Candida can be passed between sexual partners. Considerations for sexual activity include:

  • Avoiding sexual intercourse during active infection
  • Treating both partners simultaneously if recurrent infections occur
  • Using barrier methods of protection to reduce transmission risk

The Role of Steroids in Treating Yeast Infections

The use of steroids in treating yeast infections is a topic of some debate in the medical community. While steroids can provide relief from inflammation and discomfort, they must be used cautiously.

Benefits of steroid use

Mild topical steroids can offer several benefits when used appropriately:

  • Reduction of inflammation and itching
  • Faster relief of patient discomfort
  • Improved penetration of antifungal medications

Risks and precautions

However, steroid use in yeast infections comes with potential risks:

  • Possible exacerbation of the infection if used alone
  • Risk of skin thinning with prolonged use
  • Potential for masking symptoms without addressing the underlying infection

Healthcare providers may recommend short-term use of mild topical steroids as an adjuvant treatment alongside antifungal therapy. This approach can help manage symptoms while the antifungal medication addresses the root cause of the infection.

Emerging Research and Future Directions

The field of mycology, particularly regarding Candida infections, continues to evolve. Recent research has focused on several key areas that may impact future diagnosis and treatment of yeast infections with satellite lesions.

Advanced diagnostic techniques

Emerging diagnostic methods aim to provide faster and more accurate identification of Candida species:

  • Molecular techniques like PCR for rapid species identification
  • Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) for quick and accurate fungal identification
  • Development of point-of-care tests for easier diagnosis in clinical settings

Novel treatment approaches

Research into new treatment strategies for yeast infections includes:

  • Investigation of natural antifungal compounds
  • Development of new antifungal drug classes to combat resistance
  • Exploration of probiotic therapies to prevent recurrent infections

Understanding biofilm formation

Recent studies have focused on the role of Candida biofilms in persistent infections:

  • Research into biofilm-disrupting agents
  • Investigation of the relationship between biofilm formation and satellite lesions
  • Development of treatment strategies specifically targeting biofilms

As research progresses, our understanding of yeast infections and satellite lesions continues to deepen, potentially leading to more effective diagnostic and treatment strategies in the future.

Conclusion

Satellite lesions in yeast infections are a distinctive feature that can aid in diagnosis and guide treatment approaches. Understanding the characteristics, symptoms, and management of these infections is crucial for healthcare providers and patients alike. While current treatments are generally effective, ongoing research promises to bring new insights and innovative therapies to the field. By staying informed about the latest developments and maintaining good preventive practices, individuals can better manage and prevent yeast infections, improving overall health and quality of life.

Cutaneous manifestations of candidiasis – PubMed

. 1988 Apr;158(4):991-3.

doi: 10.1016/0002-9378(88)90110-x.

M McKay 
1

Affiliations

Affiliation

  • 1 Department of Dermatology, Emory University School of Medicine, Atlanta, GA.

  • PMID:

    3364512

  • DOI:

    10.1016/0002-9378(88)90110-x

M McKay.

Am J Obstet Gynecol.

1988 Apr.

. 1988 Apr;158(4):991-3.

doi: 10.1016/0002-9378(88)90110-x.

Author

M McKay 
1

Affiliation

  • 1 Department of Dermatology, Emory University School of Medicine, Atlanta, GA.

  • PMID:

    3364512

  • DOI:

    10.1016/0002-9378(88)90110-x

Abstract

Candida is identified microscopically by the observation of hyphae, linear chains of asexually budding yeast. Since these structures do not grow extensively through the stratum corneum, cutaneous samples may require Gram stain for identification. Since Candida can colonize normal tissue and also be a culture contaminant, clinicians should consider predisposing factors and clinical presentation when making a diagnosis of candidiasis. Predisposing cutaneous factors for candidiasis include occlusion, maceration, and altered barrier function. The hallmarks of Candida infection are bright erythema, fragile papulopustules, and satellite lesions. Cutaneous and mucous membrane candidiasis may differ in appearance, and sexual transmission should be considered. Treatment usually involves a topical or oral anticandidal agent, such as an imidazole. Although implicated as a predisposing factor to candidiasis, mild topical steroids can be used as short-term adjuvant treatment of these infections; when used responsibly, steroids provide antiinflammatory effects that speed relief of patient discomfort.

Similar articles

  • [Typical clinical pictures of diseases caused by saccharomyces].

    Hauck H.

    Hauck H.
    Hautarzt. 1974 Jun;25(6):303-7.
    Hautarzt. 1974.

    PMID: 4603942

    German.
    No abstract available.

  • What’s your assessment? Candida balanitis.

    Bielan B.

    Bielan B.
    Dermatol Nurs. 2003 Apr;15(2):134, 170.
    Dermatol Nurs. 2003.

    PMID: 12751348

    No abstract available.

  • [Algorithm of diagnostic procedure in candidosis of male genital organs].

    Kwaśniewska J.

    Kwaśniewska J.
    Wiad Parazytol. 2001;47 Suppl 1:113-7.
    Wiad Parazytol. 2001.

    PMID: 16897961

    Polish.

  • [Genital candidiasis].

    Ono F, Yasumoto S.

    Ono F, et al.
    Nihon Rinsho. 2009 Jan;67(1):157-61.
    Nihon Rinsho. 2009.

    PMID: 19177766

    Review.
    Japanese.

  • Itraconazole in the treatment of superficial cutaneous and mucosal Candida infections.

    Del Rosso JQ, Zellis S, Gupta AK.

    Del Rosso JQ, et al.
    J Am Osteopath Assoc. 1998 Sep;98(9):497-502.
    J Am Osteopath Assoc. 1998.

    PMID: 9785744

    Review.

See all similar articles

Cited by

  • Rare Case of Scrotal Candida albicans Infection in an Elderly Man Induced by Urinary Leakage.

    Gu AK, Kong XJ, Zhang LT.

    Gu AK, et al.
    Indian J Dermatol. 2022 Mar-Apr;67(2):169-170. doi: 10.4103/ijd.ijd_881_21.
    Indian J Dermatol. 2022.

    PMID: 36092221
    Free PMC article.

    No abstract available.

MeSH terms

Substances

Recurrent candidal intertrigo: challenges and solutions

1. Vakharia P. Intertrigo. 2017. [Accessed August 1, 2017]. http://emedicine. medscape.com/article/1087691.

2. Janniger CK, Schwartz RA, Szepietowski JC, Reich A. Intertrigo and common secondary skin infections. Am Fam Physician. 2005;72(5):833–838. [PubMed] [Google Scholar]

3. Wolf R, Oumeish OY, Parish LC. Intertriginous eruption. Clin Dermatol. 2011;29(2):173–179. [PubMed] [Google Scholar]

4. Beurey J, Weber M, Percebois G. Etude clinique et mycologique des intertrigos des pieds [Clinical and mycologic study of intertrigo of the feet] Phlebologie. 1969;22(1):73–79. French. [PubMed] [Google Scholar]

5. Coldiron BM, Manders SM. Persistent Candida intertrigo treated with fluconazole. Arch Dermatol. 1991;127(2):165–166. [PubMed] [Google Scholar]

6. de Andrade MF, Nishinari K, Puech-Leão P. Intertrigo em pacientes com linfedema de membro inferior. Correlacao clinico-laboratorial [Intertrigo in patients with lower limb lymphedema. Clinical and laboratory correlation] Rev Hosp Clin Fac Med Sao Paulo. 1998;53(1):3–5. Portuguese. [PubMed] [Google Scholar]

7. Kalra MG, Higgins KE, Kinney BS. Intertrigo and secondary skin infections. Am Fam Physician. 2014;89(7):569–573. [PubMed] [Google Scholar]

8. Katoh T. Guidelines for diagnosis and treatment of mucocutaneous candidiasis. Nihon Ishinkin Gakkai zasshi [Jap J Med Mycol.] 2009;50(4):207–212. Japanese. [PubMed] [Google Scholar]

9. Metin A, Dilek N, Demirseren DD. Fungal infections of the folds (intertriginous areas) Clin Dermatol. 2015;33(4):437–447. [PubMed] [Google Scholar]

10. Tüzün Y, Wolf R, Bağlam S, Engin B. Diaper (napkin) dermatitis: a fold (intertriginous) dermatosis. Clin Dermatol. 2015;33(4):477–482. [PubMed] [Google Scholar]

11. Veraldi S. Rapid relief of intertrigo-associated pruritus due to Candida albicans with isoconazole nitrate and diflucortolone valerate combination therapy. Mycoses. 2013;56(Suppl 1):41–43. [PubMed] [Google Scholar]

12. Bahmaei M, Dehghan P, Kachuei R, Babaei H, Mohammadi R. Interdigital intertrigo due to Fusarium oxysporum. Curr Med Mycol. 2016;2(1):43–46. [PMC free article] [PubMed] [Google Scholar]

13. Bissan AT, Iken M, Doumbia M, Ou-Khedda N, El Alaoui M, Lmimouni B. Fusarioses superficielles a Fusarium solani chez un immunocompetent et un immunodeprime diagnostiquees a l’Hopital militaire de Rabat [Fusarioses to Fusarium solani in an immunocompetent and immunocompromised diagnosed in military hospital of Rabat] J Mycol Med. 2017;27(3):382–386. French. [PubMed] [Google Scholar]

14. Diongue K, Ndiaye M, Badiane AS, et al. Intertrigo interorteils a Fusarium solani a Dakar [Tinea pedis due to Fusarium solani in Dakar] J Mycol Med. 2015;25(2):155–158. French. [PubMed] [Google Scholar]

15. Diongue K, Ndiaye M, Diallo MA, et al. Fungal interdigital tinea pedis in Dakar (Senegal) J Mycol Med. 2016;26(4):312–316. [PubMed] [Google Scholar]

16. Néji S, Trabelsi H, Cheikhrouhou F, et al. Fusarioses diagnostiquees au laboratoire d’un CHU en Tunisie: etude epidemiologique, clinique et mycologique [Fusariosis diagnosed in the laboratory of an UH in Tunisia: epidemiological, clinical and mycological study] J Mycol Med. 2013;23(2):130–135. French.aw. [PubMed] [Google Scholar]

17. Romano C, Presenti L, Massai L. Interdigital intertrigo of the feet due to therapy-resistant Fusarium solani. Dermatology. 1999;199(2):177–179. [PubMed] [Google Scholar]

18. Varon AG, Nouer SA, Barreiros G, et al. Superficial skin lesions positive for Fusarium are associated with subsequent development of invasive fusariosis. J Infect. 2014;68(1):85–89. [PubMed] [Google Scholar]

19. Bazin JC, Hutinel B. Intertrigos mycosiques et lymphangites [Fungal intertrigo and lymphangitis (author’s transl)] J Mal Vasc. 1980;5(2):107–108. French. [PubMed] [Google Scholar]

20. Karaca S, Kulac M, Cetinkaya Z, Demirel R. Etiology of foot intertrigo in the District of Afyonkarahisar, Turkey: a bacteriologic and mycologic study. J Am Podiatr Med Assoc. 2008;98(1):42–44. [PubMed] [Google Scholar]

21. de González MI, Mendoza M, Bastardo de Albornoz M, Apitz-Castro R. Efectos del ajoeno sobre dermatofitos, Candida albicans y Malassezia furfur [Activity of ajoene on dermatophytes, Candida albicans and Malassezia furfur. ] Rev Iberoam Micol. 1998;15(4):277–281. Spanish. [PubMed] [Google Scholar]

22. Katoh T, Kagawa S, Ishimoto M. Malassezia intertrigo, a new clinical entity. Mycoses. 1988;31(11):558–562. [PubMed] [Google Scholar]

23. Gorani A, Oriani A, Klein EF, Veraldi S. Case report. Erythrasmoid pityriasis versicolor. Mycoses. 2001;44(11–12):516–517. [PubMed] [Google Scholar]

24. Beaulieu P, Le Guyadec T, Ponties-Leroux B, Boutchnei S, Grossetete G, Millet P. Cas pour diagnostic: intertrigo a Pseudomonas aeruginoasa [A case for diagnosis: Pseudomonas aeruginosa intertrigo] Ann Dermatol Venereol. 1992;119(3):223–225. French. [PubMed] [Google Scholar]

25. Block SL. Tricky triggers of intertrigo. Pediatr Ann. 2014;43(5):171–176. [PubMed] [Google Scholar]

26. Dekio I, Matsuki S, Morita E. High carriage rate of Staphylococcus aureus and Streptococcus agalactiae in nine cases of fungus-free intertrigo of the toe cleft. Int J Dermatol. 2014;53(4):484–486. [PubMed] [Google Scholar]

27. Adisen E, Onder M. Viral infections of the folds (intertriginous areas) Clin Dermatol. 2015;33(4):429–436. [PubMed] [Google Scholar]

28. Bandyopadhyay D, Ghosh SK. Mucocutaneous features of Chikungunya fever: a study from an outbreak in West Bengal, India. Int J Dermatol. 2008;47(11):1148–1152. [PubMed] [Google Scholar]

29. Calikoglu E, Soravia-Dunand VA, Perriard J, Saurat JH, Borradori L. Acute genitocrural intertrigo: a sign of primary human immunodeficiency virus type 1 infection. Dermatology. 2001;203(2):171–173. [PubMed] [Google Scholar]

30. Yell JA, Sinclair R, Mann S, Fleming K, Ryan TJ. Human papillomavirus type 6-induced condylomata: an unusual complication of intertrigo. Br J Dermatol. 1993;128(5):575–577. [PubMed] [Google Scholar]

31. López-Martinez R. Candidosis, a new challenge. Clin Dermatol. 2010;28(2):178–184. [PubMed] [Google Scholar]

32. Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;26(4):e1–e50. [PMC free article] [PubMed] [Google Scholar]

33. Pfaller MA, Andes DR, Diekema DJ, et al. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) Registry 2004–2008. PLoS ONE. 2014;9(7):e101510. [PMC free article] [PubMed] [Google Scholar]

34. Sullivan DJ, Westerneng TJ, Haynes KA, Bennett DE, Coleman DC. Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology. 1995;141(Pt 7):1507–1521. [PubMed] [Google Scholar]

35. Kashem SW, Kaplan DH. Skin immunity to Candida albicans. Trends Immunol. 2016;37(7):440–450. [PMC free article] [PubMed] [Google Scholar]

36. Kühbacher A, Burger-Kentischer A, Rupp S. Interaction of Candida species with the skin. Microorganisms. 2017;5(2):32. [Google Scholar]

37. Mayer FL, Wilson D, Hube B. Candida albicans pathogenicity mechanisms. Virulence. 2014;4(2):119–128. [PMC free article] [PubMed] [Google Scholar]

38. Naglik JR, Moyes DL, Wachtler B, Hube B. Candida albicans interactions with epithelial cells and mucosal immunity. Microbes Infect. 2011;13(12–13):963–976. [PMC free article] [PubMed] [Google Scholar]

39. Höfs S, Mogavero S, Hube B. Interaction of Candida albicans with host cells: virulence factors, host defense, escape strategies, and the microbiota. J Microbiol. 2016;54(3):149–169. [PubMed] [Google Scholar]

40. Brown GD. Innate antifungal immunity: the key role of phagocytes. Annu Rev Immunol. 2011;29:1–21. [PMC free article] [PubMed] [Google Scholar]

41. Qin Y, Zhang L, Xu Z, et al. Innate immune cell response upon Candida albicans infection. Virulence. 2016;7(5):512–526. [PMC free article] [PubMed] [Google Scholar]

42. Moyes DL, Runglall M, Murciano C, et al. A biphasic innate immune MAPK response discriminates between the yeast and hyphal forms of Candida albicans in epithelial cells. Cell Host Microbe. 2010;8(3):225–235. [PMC free article] [PubMed] [Google Scholar]

43. Schaller M, Mailhammer R, Grassl G, Sander CA, Hube B, Korting HC. Infection of human oral epithelia with Candida species induces cytokine expression correlated to the degree of virulence. J Invest Dermatol. 2002;118(4):652–657. [PubMed] [Google Scholar]

44. Villar CC, Kashleva H, Mitchell AP, Dongari-Bagtzoglou A. Invasive phenotype of Candida albicans affects the host proinflammatory response to infection. Infect Immun. 2005;73(8):4588–4595. [PMC free article] [PubMed] [Google Scholar]

45. Weindl G, Naglik JR, Kaesler S, et al. Human epithelial cells establish direct antifungal defense through TLR4-mediated signaling. J Clin Invest. 2007;117(12):3664–3672. [PMC free article] [PubMed] [Google Scholar]

46. Wang X, van de Veerdonk FL, Netea MG. Basic genetics and immunology of Candida infections. Infect Dis Clin North Am. 2016;30(1):85–102. [PubMed] [Google Scholar]

47. Guidelines of care for superficial mycotic infections of the skin: mucocutaneous candidiasis. Guidelines/Outcome Committee. American Academy of Dermatology. J Am Acad Dermatol. 1996;34(1):110–115. [PubMed] [Google Scholar]

48. De Britto LJ, Yuvaraj J, Kamaraj P, Poopathy S, Vijayalakshmi G. Risk factors for chronic intertrigo of the lymphedema leg in southern India: a case-control study. Int J Low Extrem Wounds. 2015;14(4):377–383. [PubMed] [Google Scholar]

49. Hay RJ, Ashbee HR. Fungal infections. In: Griffiths C, Barker J, Bleiker T, Chalmers R, Creamer D, editors. Rook’s Textbook of Dermatology. 9th. Chichester, West Sussex: John Wiley & Sons Inc; 2016. pp. 32.56–32.70. [Google Scholar]

50. Hessen MT, Walsh SR, Ferri FF. Mucocutaneous candidiasis. 2010. [Accessed August 8, 2017]. https://www.clinicalkey.com/-!/content/medical_topic/21-s2.0-1014515.

51. James WD, Andrews GC, Berger TG, Elston DM. Diseases resulting from fungi and yeasts. In: James WD, Berger T, Elston D, editors. Andrews’ Diseases of the Skin: Clinical Dermatology. 12th. Philadelphia, PA: Saunders Elsevier; 2016. pp. 285–318. [Google Scholar]

52. Lisboa C, Santos A, Dias C, Azevedo F, Pina-Vaz C, Rodrigues A. Candida balanitis: risk factors. J Eur Acad Dermatol Venereol. 2010;24(7):820–826. [PubMed] [Google Scholar]

53. Lu SY. Perception of iron deficiency from oral mucosa alterations that show a high prevalence of Candida infection. J Formos Med Assoc. 2016;115(8):619–627. [PubMed] [Google Scholar]

54. Mamatha KV, Shubha U, Jain CM. Clinical evaluation of the efficacy of Khadiradi yoga avachoornana in Kachchu with special reference to genitoinguinal intertrigo. Ayu. 2010;31(4):461–465. [PMC free article] [PubMed] [Google Scholar]

55. Ndiaye M, Taleb M, Diatta BA, et al. Etiology of intertrigo in adults: a prospective study of 103 cases. J Mycol Med. 2017;27(1):28–32. [PubMed] [Google Scholar]

56. Rockwell PG. Acute and chronic paronychia. Am Fam Physician. 2001;63(6):1113–1116. [PubMed] [Google Scholar]

57. Ryan KJ, Ray CG. Candida, Aspergillus, Pneumocystis, and other opportunistic fungi. In: Ryan KJ, Ray CG, editors. Sherris Medical Microbiology. 6th. New York: McGraw-Hill Education Medical; 2014. pp. 729–743. [Google Scholar]

58. Scheinfeld NS. Cutaneous candidiasis. 2017. [Accessed August 8, 2017]. http://emedicine.medscape.com/article/1090632-overview.

59. Sharon V, Fazel N. Oral candidiasis and angular cheilitis. Dermatol Ther. 2010;23(3):230–242. [PubMed] [Google Scholar]

60. Silverman RA, Schwartz RH. Streptococcal intertrigo of the cervical folds in a five-month-old infant. Pediatr Infect Dis J. 2012;31(8):872–873. [PubMed] [Google Scholar]

61. Sparber F, LeibundGut-Landmann S. Interleukin 17-mediated host defense against Candida albicans. Pathogens. 2015;4(3):606–619. [PMC free article] [PubMed] [Google Scholar]

62. Asiedu DK. Candidiasis, cutaneous. In: Ferri FF, editor. Ferri’s Clinical Advisor 2018: 5 Books in 1. Amsterdam: Elsevier Science Health Science; 2017. pp. 234–235.e231. [Google Scholar]

63. Habif TP. Superficial fungal infections. In: Habif TP, editor. Clinical Dermatology: A Color Guide to Diagnosis and Therapy. 6th. Philadelphia, PA: Saunders; 2016. pp. 487–533. [Google Scholar]

64. Hay RJ. Fungal infections of the skin. In: Olafsson JH, Hay RJ, editors. Antibiotic and Antifungal Therapies in Dermatology. Switzerland: Springer; 2016. pp. 157–186. [Google Scholar]

65. Kauffman CA. Candidiasis. In: Goldman L, Schafer AI, editors. Goldman-Cecil Medicine. 25th. Philadelphia, PA: Elsevier/Saunders; 2016. pp. 2079–2083.e2072. [Google Scholar]

66. Mistiaen P, van Halm-Walters M. Prevention and treatment of intertrigo in large skin folds of adults: a systematic review. BMC Nurs. 2010;9:12. [PMC free article] [PubMed] [Google Scholar]

67. Wilmer EN, Hatch RL. Resistant “candidal intertrigo”: could inverse psoriasis be the true culprit? J Am Board Fam Med. 2013;26(2):211–214. [PubMed] [Google Scholar]

68. Valenti L. Topical treatment of intertriginous candidal infection. Mycoses. 2008;51(Suppl 4):44–45. [PubMed] [Google Scholar]

69. Terzieva K, Elsner P. A case of intertrigo resistant to treatment – what is your diagnosis? J Dtsch Dermatol Ges. 2015;13(2):169–171. [PubMed] [Google Scholar]

70. Smith SM, Milam PB, Fabbro SK, Gru AA, Kaffenberger BH. Malignant intertrigo: a subset of toxic erythema of chemotherapy requiring recognition. JAAD Case Rep. 2016;2(6):476–481. [PMC free article] [PubMed] [Google Scholar]

71. Santiago-et-Sanchez-Mateos JL, Beà S, Fernández M, Pérez B, Harto A, Jaén P. Botulinum toxin type A for the preventive treatment of intertrigo in a patient with Darier’s disease and inguinal hyperhidrosis. Dermatol Surg. 2008;34(12):1733–1737. [PubMed] [Google Scholar]

72. Nazzaro G, Vaira F, Coggi A, Gianotti R. A 42-year-old woman with a submammary intertrigo. Int J Dermatol. 2013;52(9):1035–1036. [PubMed] [Google Scholar]

73. López-Corominas V, Yagüe F, Knöpfel N, et al. Streptococcus pyogenes cervical intertrigo with secondary bacteremia. Pediatr Dermatol. 2014;31(2):e71–e72. [PubMed] [Google Scholar]

74. Imam TH, Cassarino D, Patail H, Khan N. Refractory intertrigo in the right inguinal crease: challenge. Am J Dermatopathol. 2017;39(8):629. [PubMed] [Google Scholar]

75. Dowd ML, Ansell LH, Husain S, Grossman ME. Papular acantholytic dyskeratosis of the genitocrural area: a rare unilateral asymptomatic intertrigo. JAAD Case Rep. 2016;2(2):132–134. [PMC free article] [PubMed] [Google Scholar]

76. McKay C, McBride P, Muir J. Plantar verrucous carcinoma masquerading as toe web intertrigo. Australas J Dermatol. 2012;53(2):e20–e22. [PubMed] [Google Scholar]

77. Butragueño Laiseca L, Toledo Del Castillo B, Marañón Pardillo R. Cervical intertrigo: think beyond fungi. Rev Chil Pediatr. 2016;87(4):293–294. [PubMed] [Google Scholar]

78. Kirkpatrick CH. Chronic mucocutaneous candidiasis. Pediatr Infect Dis J. 2001;20(2):197–206. [PubMed] [Google Scholar]

79. Hoeger PH, Stark S, Jost G. Efficacy and safety of two different antifungal pastes in infants with diaper dermatitis: a randomized, controlled study. J Eur Acad Dermatol Venereol. 2010;24(9):1094–1098. [PubMed] [Google Scholar]

80. Blanco D, van Rossem K. A prospective two-year assessment of miconazole resistance in Candida spp with repeated treatment with 025% miconazole nitrate ointment in neonates and infants with moderate to severe diaper dermatitis complicated by cutaneous candidiasis. Pediatr Dermatol. 2013;30(6):717–724. [PubMed] [Google Scholar]

81. Chiriac A, Chiriac AE, Pinteala T, Foia L, Brzezinski P. Erosio blastomycetica interdigitale sign of Candidiasis and diabetes! Bangladesh J Med Sci. 2014;13(1):105–106. [Google Scholar]

82. Adams SP. Dermacase. Erosio interdigitalis blastomycetica. Can Fam Physician. 2002;48:271–277. [PMC free article] [PubMed] [Google Scholar]

83. Gjessing HC. Intertrigo; saerlig omtale av perianal, (retro) aurikulaer og periokulaer intertrigo [Intertrigo, with special consideration on perianal, retroauricular and periocular intertrigo] Tidsskr Nor Laegeforen. 1953;73(12):488–490. Norwegian. [PubMed] [Google Scholar]

84. Parker ER, Dellavalle RP, Rosen T, Ofori AO. Candidal intertrigo. 2013. [Accessed August 12, 2017]. last updated Jul 2017; https://www.uptodate.com/contents/candidal-intertrigo/

85. Tulipan L. Intertrigo (chafing) treated with tannic acid and brilliant green. J Am Med Ass. 1941;116(14):1518–1519. [Google Scholar]

86. Dogan B, Karabudak O. Treatment of candidal intertrigo with a topical combination of isoconazole nitrate and diflucortolone valerate. Mycoses. 2008;51(Suppl 4):42–43. [PubMed] [Google Scholar]

87. Janik MP, Heffernan MP. Yeast infections: candidiasis and tinea (pityriasis) versicolor. In: Wolf K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, editors. Fitzpatrick’s Dermatology in General Medicine. 7th. New York: McGraw-Hill Medical; 2008. pp. 1822–1830. [Google Scholar]

88. Verma S, Heffernan M. Fungal infections. In: Wolff K, Goldsmith L, Katz S, Gilchrest B, Paller A, Leffell D, editors. Fitzpatrick’s Dermatology in General Medicine. 7th. New York: McGraw-Hill Medical; 2008. pp. 1807–1821. [Google Scholar]

89. Elewski BE, Hughey LC, Sobera JO, Hay R. Fungal diseases. In: Bolognia JL, Jorizzo JL, Schaffer JV, editors. Dermatology. 3rd. [Edinburgh]: Elsevier/Saunders; 2012. pp. 1251–1284. [Google Scholar]

90. Rowen JL. Mucocutaneous candidiasis. Semin Perinatol. 2003;27(5):406–413. [PubMed] [Google Scholar]

91. Rashid A. Arthroconidia as vectors of dermatophytosis. Cutis. 2001;67(5 Suppl):23–23. [PubMed] [Google Scholar]

92. Pryzbilla B, Rueff F. Contact dermatitis. In: Burgdorf WHC, Braun-Falco O, editors. Braun-Falco’s Dermatology. 3rd. Heidelberg: Springer; 2009. pp. 491–540. [Google Scholar]

93. Reiss E, Shadomy HJ, Lyon GM. Fundamental Medical Mycology. Hoboken, NJ: John Wiley & Sons; 2012. pp. 250–301. [Google Scholar]

94. Loo DS. Cutaneous fungal infections in the elderly. Dermatol Clin. 2004;22(1):33–50. [PubMed] [Google Scholar]

95. Draijer LW, Folmer H. NHG-Farmacotherapeutische richtlijn Intertrigo. Huisarts en Wetenschap. 2007;50(1):33–35. [Google Scholar]

96. Bazex J. Intertrigo. Diagnostic orientation. Rev Prat. 1992;42(13):1689–1692. [PubMed] [Google Scholar]

97. Benkalfate L, Zein K, le Gall F, Chevrant-Breton J, Rivalan J, le Pogamp P. Calcified intertrigo, a rare cause of cutaneous calcinosis. Ann Dermatol Venereol. 1995;122(11–12):789–792. [PubMed] [Google Scholar]

98. Carleton A. A case of pseudomembiunous intertrigo. Br J Dermatol. 1943;55(6):154–158. [Google Scholar]

99. Collier C. Within the fold: treatments of intertrigo. JAAD. 2007;56(2):AB126. [Google Scholar]

100. Honig PJ, Frieden IJ, Kim HJ, Yan AC. Streptococcal intertrigo: an underrecognized condition in children. Pediatrics. 2003;112(6 Pt 1):1427–1429. [PubMed] [Google Scholar]

101. Ke CL, Chen CC, Lin CT, Chen GS, Chai CY, Cheng ST. Fluvoxamine-induced bullous eruption mimicking hand-foot syndrome and intertrigo-like eruption: rare cutaneous presentations and elusive pathogenesis. J Am Acad Dermatol. 2006;55(2):355–356. [PubMed] [Google Scholar]

102. Korver GE, Ronald H, Petersen MJ. An intertrigo-like eruption from pegylated liposomal doxorubicin. J Drugs Dermatol. 2006;5(9):901–902. [PubMed] [Google Scholar]

103. Plaza AI, Sancho MI, Millet PU, et al. Erythematous, vesicular, and circinate lesions in a 78-year-old female – benign familial pemphigus. An Bras Dermatol. 2017;92(3):439–440. [PMC free article] [PubMed] [Google Scholar]

104. Millsop JW, Fazel N. Oral candidiasis. Clin Dermatol. 2016;34(4):487–494. [PubMed] [Google Scholar]

105. Sundaram SV, Srinivas CR, Thirumurthy M. Candidal intertrigo: treatment with filter paper soaked in Castellani’s paint. Indian J Dermatol Venereol Leprol. 2006;72(5):386–387. [PubMed] [Google Scholar]

106. Chadbourne EB, Zhang S, Gordon MJ, et al. Clinical outcomes in reduction mammaplasty: a systematic review and meta-analysis of published studies. Mayo Clin Proc. 2001;76(5):503–510. [PubMed] [Google Scholar]

107. Ding X, Yan D, Sun W, Zeng Z, Su R, Su J. Epidemiology and risk factors for nosocomial non-Candida albicans candidemia in adult patients at a tertiary care hospital in North China. Med Mycol. 2015;53(7):684–690. [PubMed] [Google Scholar]

Yeast infections (fungus) in women

Every woman will experience a yeast infection at some point in her life. A yeast infection is an irritating infection of the vagina and vulva that causes itching, discharge, and irritation. This is a type of vaginitis caused by an overgrowth of a yeast known as Candida albicans and is often easily treated at home, but can sometimes be severe enough to require a visit to a doctor.

On average, three out of four women experience a yeast infection. Some women have several throughout their lives. Although this disease is not considered a sexually transmitted disease, the fungus can be spread through oral contact with the female genitalia. It is important to be aware of the signs and symptoms of a yeast infection and when you should see your OB/GYN.

Signs and symptoms of yeast infections

Signs and symptoms of a vaginal yeast infection can range from mild to more severe. These include the following:

  • burning sensation, especially when urinating or during intercourse;
  • itching and irritation in the vagina and vulva;
  • redness and swelling of the vulva;
  • thick, white or greyish vaginal discharge resembling cottage cheese;
  • vaginal rash;
  • pain and soreness in the vagina;
  • watery vaginal discharge.

Yeast infection risk factors

There are certain risk factors that can lead to the development of a yeast infection. These include the following:

  • taking antibiotics;
  • lack of sleep;
  • hormonal imbalance during the menstrual cycle;
  • taking hormone therapy or oral contraceptives;
  • stress;
  • malnutrition, especially when eating too many sugary foods;
  • pregnancy;
  • diabetes;
  • weakened immune system;
  • wearing clothes that are too tight.

A yeast infection can be caused by a number of reasons, but the most common cause is the fungus Candida albicans. The vagina has a natural balance of this substance, as well as other bacteria. However, in some cases there may be an overgrowth of Candida, leading to the development of a yeast infection. As a result, you may experience a combination of classic symptoms such as burning, itching, and soreness. Even women who are not sexually active can develop this infection.

Sometimes other types of Candida can also cause a yeast infection, but most drugs, especially over-the-counter ones, are for Candida albicans. If you develop a yeast infection caused by another type of Candida, treatment may be more difficult. If more aggressive treatment is needed, you may need to make an appointment with an OB/GYN.

Diagnosis of yeast infections

When you visit your OB/GYN, the doctor will run a test to determine if you have a yeast infection:

  • Review of medical history, including any past vaginal infections or sexually transmitted diseases.
  • Visual examination of the pelvis, external and internal parts of the vagina.
  • Biosampling, a sample of vaginal secretions, to determine what type of fungus is causing the infection.

Yeast infection treatment

Treatment for a simple yeast infection is usually straightforward for most women and may include the following options:

  • Prescription antifungal cream, ointment, suppositories, or tablets that last one, three, or seven days.
  • Single dose oral preparations
  • An over-the-counter antifungal cream or suppository that lasts three to seven days.

For more complex yeast infections, a doctor may suggest the following treatment options:

  • Prescription antifungal cream, ointment, suppositories, or tablets that last up to 14 days.
  • Multi-dose oral preparations.
  • Maintenance plan for recurrent yeast infections. (This type of treatment usually lasts longer than 14 days and may require oral medication once a week for six months or vaginal suppositories once a week.)

Visit your obstetrician-gynecologist. A yeast infection can be uncomfortable and affect your emotional state, but the problem is treatable. Check with your doctor so you can take action in time to avoid infection in the future.

Vulvovaginal candidiasis | Dikul Center

Vulvovaginal candidiasis is a fungal infection that causes irritation, discharge, and severe itching in the vagina and vulva, the tissues at the entrance to the vagina.

Vaginal yeast infection develops in up to 70% of women during their lifetime, and many of these episodes may occur several times.

Vaginal candidiasis is not a sexually transmitted infection. But the first regular sex life significantly increases the risk of developing candidiasis. Also, candidiasis can be associated with oral-genital sex.

Vaginal yeast infections respond well to treatment. In the presence of recurrent yeast infection – four or more times during the year – the patient may need long-term maintenance therapy.

Symptoms

Symptoms of candidiasis can range from mild to moderate and include:

  • Feelings of itching and irritation in the vagina and vulva
  • Burning sensation when urinating or during intercourse.
  • Redness and swelling of the vulva
  • Vaginal pain and tenderness
  • Vaginal rash
  • Thick white cheesy vaginal discharge, odorless.
  • Watery vaginal discharge

Complicated candidiasis

A woman may have a yeast infection if:

  • There are severe symptoms such as extensive redness, swelling, and itching that are complicated by tears, cracks, or sores.
  • If yeast infection develops more than four times a year
  • Infection due to an atypical fungus
  • Pregnancy
  • Uncontrolled diabetes
  • Weakening of the immune system due to the use of certain medications or the presence of serious diseases such as HIV infection.

When to see a doctor?

You need to make an appointment with a doctor if:

  • Symptoms of a yeast infection appear for the first time
  • It is doubtful that this is a fungal infection
  • Symptoms do not improve after taking over-the-counter antifungal vaginal creams or suppositories.
  • Other symptoms appear

Causes

Candida albicans is the main cause of most vaginal yeast infections.

The vagina is known to naturally contain a balanced mixture of yeast, including Candida, and bacteria. Some bacteria (lactobacilli) prevent yeast from growing.

But this balance can be upset. Overgrowth of fungi or their penetration into the deeper layers of the mucous tissue of the vagina can lead to the development of symptoms of a yeast infection.

Yeast overgrowth can be caused by:

  • The use of antibiotics, which can upset the balance of the natural vaginal flora
  • Pregnancy
  • Uncontrolled diabetes
  • Immune system disorders
  • Taking contraceptives or hormone therapy, which can increase the level of estrogen in the blood.

Candida albicans is the most common type of fungus that causes yeast infections. Yeast infections caused by other types of Candida are much more difficult to treat and usually require more aggressive treatments.

Risk factors

Factors that increase the risk of fungal infection include:

  • Taking antibiotics. A yeast infection is not uncommon in women who take antibiotics. Broad-spectrum antibiotics kill not only a number of bacteria, but also the normal microflora in the vagina, which can cause yeast overgrowth.
  • Increased estrogen levels contribute to the development of yeast infections. This can be both pregnant women and women who use high-dose estrogen birth control pills or if estrogen hormone therapy is being performed.
  • Uncontrolled diabetes. Women with poor control and high blood sugar levels are more at risk of developing fungal infections than women who control their blood sugar levels.
  • Immune system disorders. Women who are immunosuppressed, such as after corticosteroid therapy or HIV infection, are more at risk of yeast infections.

Prevention

To reduce the risk of vaginal yeast infections, it is recommended to wear underwear that is not too tight with a cotton gusset.

Also recommended:

  • Do not use tight fitting tights
  • Use douching as this flushes out some of the normal bacteria in the vagina that protect against infection.
  • Use scented products for women frequently, such as bubble baths, pads, and tampons.
  • Very hot and whirlpool baths are not recommended
  • Do not take antibiotics unnecessarily, such as for colds or other viral infections.
  • Avoid prolonged exposure to wet clothing such as swimwear and sportswear.

Diagnosis

To diagnose thrush, the doctor can:

  • Ask questions about symptoms and medical history. It is important for the physician to collect information about past vaginal or sexually transmitted infections.
  • Perform a gynecological examination. The doctor will examine the external genitalia to look for signs of a fungal infection. Then the doctor will examine the vagina and cervix using a special speculum.
  • Collect vaginal secretions. The doctor may send a sample of vaginal fluid for analysis to determine the type of fungus that caused the yeast infection. Identifying the fungus can help your doctor decide on the appropriate treatment, especially if you have recurrent yeast infections.

Treatment

Treatment for yeast infections depends on the severity and frequency of infections.

For mild to moderate symptoms and infrequent episodes, your doctor may recommend:

  • Short-term vaginal therapy. Taking antifungal medications for three to seven days usually clears up the yeast infection. Antifungal drugs, in the form of creams, ointments, tablets and suppositories, include miconazole (monistat 3) and terconazole. Some of these medicines can be purchased without a prescription, while others are available by prescription only.
  • Single oral dose. Your doctor may prescribe a single oral dose of fluconazole (Diflucan). But taking such drugs is contraindicated during pregnancy. In the presence of severe symptoms, it is possible to take two single doses with an interval of three days.

Seek medical attention again if treatment does not relieve symptoms or if symptoms return within two months.

If you have severe symptoms or have frequent yeast infections, your doctor may recommend:

  • Long-term vaginal therapy.